Market Overview

UPDATE: Jeffries Initiates MedAssets at Buy on Attractive Pricing

Share:

In a report published on Tuesday, Jefferies analyst Sean Dodge initiated coverage on MedAssets (NASDAQ: MDAS) with a Buy rating and $23 price target on the company.

In the report, Jeffries commented, "Attractively Priced Play on Healthcare Reform. Demand for MedAssets capabilities will grow as healthcare reform progresses and hospitals struggle with: (1) increasing reimbursement pressures; (2) the transition from fee-for-service to fee-for-value-based reimbursement models; (3) growing patient self-pay A/R mixes; (4) the migration to ICD-10; and (5) decentralized and inefficient procurement practices. Notably, the stock has one of the cheapest valuations in its peer group in terms of both adjusted P/E and FCF (yield)."

MedAssets closed on Monday at $19.25.

Latest Ratings for MDAS

DateFirmActionFromTo
Jan 2016TerminatesNeutral
Nov 2015AssumesNeutral
Nov 2015DowngradesBuyNeutral

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Jefferies Sean DodgeAnalyst Color Initiation Analyst Ratings

 

Related Articles (MDAS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DNKNGuggenheimMaintains86.0
KSURaymond JamesReiterates188.0
DLTRKeyBancDowngrades
MSCitigroupDowngrades
WTRB of A SecuritiesDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com